Patent Attorney's Docket No. <u>001560-390</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of)						
Haruka	azu FUKAMI et al) Group Art Unit: 1624						
Application No.: 09/763,213) Examiner: To be assigned)						
Filed:	February 20, 2001)						
For:	DESCRIPTION QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF)))						
	AMENDMENT/REPLY TRANSMITTAL LETTER							
	ant Commissioner for Patents ington, D.C. 20231							
Sir: E a pp lic	inclosed is a Supplemental Preliminary Ame	ndment for the above-identified patent						
[•	A Petition for Extension of Time is also enclosed.						
ί	A Terminal Disclaimer and a check for requisite Government fee are also encl	A Terminal Disclaimer and a check for [] \$55.00 (248) [] \$110.00 (148) to cover the requisite Government fee are also enclosed.						
ī	Also enclosed is	Also enclosed is						
Į	[] Small entity status is hereby claimed.							
ſ	[] \$355.00 (279) [] \$710.00 (179) fee d	Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [] \$355.00 (279) [] \$710.00 (179) fee due under 37 C.F.R. § 1.17(e).						
	[] Applicant(s) previously submitted, on, for which continued examination is requested.							
i	exceed three months from the filing of	Applicant(s) request suspension of action by the Office until at least _, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.						
!	[] A Request for Entry and Consideratio (146/246) is also enclosed.	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.						
	[X] No additional claim fee is required.							
	An additional claim fee is required, and is calculated as shown below:							



Amendment/Reply Transmittal Letter Application No. <u>09/763,213</u> Attorney's Docket No. <u>001560-390</u> Page 2

	AMENDED CLAIMS				
	No. Of Claims	Highest No. Of Claims Previously Paid for	Extra Claims	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (103) =	
Independent Claims		MINUS =		× \$80.00 (102) =	
If Amendment adds m	ultiple depende	nt claims, add \$270	.00 (104)		
Total Amendment Fee					
If small entity status is	claimed, subt	act 50% of Total A	mendment Fe		
TOTAL ADDITIONA	AL FEE DUE	FOR THIS AMEN	DMENT		

L	1	A claim fee in u	e amount of \$	is enclosed.
[]	Charge \$	to Deposit Account	t No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Registration No. 36,607

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: May 30, 2001

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this Amendment/Reply Transmittal is being filed in the U.S. Patent and Trademark Office, together with the attached Supplemental Preliminary Amendment, on the date shown below.

5/30/0/

#613 PS 6/11/0

Patent Attorney's Docket No. 001560-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of)		
Harukazu FUKAMI et al)	Group Art Unit:	1624
Applic	ation No.: 09/763,213)	Prior Examiner:	To be assigned
Filed:	February 20, 2001)		
For:	DESCRIPTION QUINAZOLINE	į		•
	DERIVATIVES AND)		
	PHARMACEUTICAL)		
	ADDITIONS THEREOF)		

SUPPLEMENTAL PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants filed a Preliminary Amendment on February 20, 2001. In accordance with the new PTO rules and procedures, applicants provide herewith a clean set of claims, as well as a marked-up copy.

IN THE CLAIMS

Please replace claims 3-6 as follows.

(Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein in the formula (1), R² is a carboxylic acid group or a hydrogen atom.

(10/00)